# Enliven Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/enliven-therapeutics

- Industry: Biotechnology
- Headquarters: Boulder, US
- Website: www.enliventherapeutics.com
- Total disclosed funding: $85M
- Latest round: Series B (Jan 19, 2022)
- Investors on record: 8

## About

Based in Colorado, US, and founded in 2019, Enliven Therapeutics, Inc. operates as a precision oncology company. Sam Kintz (CEO), Joe Lyssikatos, and Anish Patel are the co-founders of the company. In February 2022, Enliven Therapeutics, Inc. raised USD 85 million in series B funding co-led by new investors Cormorant Asset Management and Surveyor Capital, with participation from other new investors.

The company is a biopharmaceutical company that focuses on the discovery and development of small molecule inhibitors to help cancer patients by combining clinically validated biological targets with industry-leading chemistry to address the limitations of existing therapies, providing the healthcare sector with new techniques, and assisting patients in extending and improving their lives.

## Funding rounds

- Series B, Jan 19, 2022, $85M — Cormorant Asset Management, Boxer Capital, Janus Henderson Investors, Surveyor Capital, Logos Capital
- Series A, Dec 7, 2020 — OrbiMed Advisors, 5AM Ventures, Roche Venture Fund
- Seed, Jun 1, 2019 — OrbiMed Advisors, 5AM Ventures

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Seed, Series A
- 5AM Ventures (https://capitalatlas.ai/funds/5am-ventures) — Seed, Series A
- Roche Venture Fund (https://capitalatlas.ai/funds/roche-venture-fund) — Series A
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series B
- Boxer Capital (https://capitalatlas.ai/funds/boxer-capital) — Series B
- Janus Henderson Investors — Series B
- Surveyor Capital — Series B
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series B